Return to CG180 Overview

Atrial fibrillation: management [CG180]

Measuring the use of this guidance

Recommendation: 1.4.1

Use the CHA2DS2-VASc stroke risk score to assess stroke risk in people with any of the following: •symptomatic or asymptomatic paroxysmal, persistent or permanent atrial fibrillation •atrial flutter •a continuing risk of arrhythmia recurrence after cardioversion back to sinus rhythm.

What was measured: AF006: The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more)
Data collection end: March 2016
94.2%
Data collection end: March 2017
93.5%
Area covered: National
Source: Health and Social Care Information Centre. Quality and Outcomes Framework.


Recommendation: 1.5.3

Offer anticoagulation to people with a CHA2DS2-VASc score of 2 or above, taking bleeding risk into account.

What was measured: AF007: In those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more, the percentage of patients who are currently treated with anti-coagulation drug therapy.
Data collection end: March 2016
77.9%
Data collection end: March 2017
81.2%
Area covered: National
Source: Health and Social Care Information Centre. Quality and Outcomes Framework.



 Return to CG180 Overview